Suzhou Kintor Pharma announced a global partnership with Predicine, a US-China diagnostics company, using Predicine’s GeneRADAR, a ctRNA + ctDNA liquid biopsy. Predicine will develop biomarkers for Kintor’s oncology drugs. Over the past two years, Kintor and Predicine have formed multiple collaborations to support China-US Phase I-III clinical trials of Kintor’s lead candidate, proxalutamide, as a treatment for prostate and breast cancer. Predicine says GeneRADAR is the first liquid biopsy to test both circulating RNA and DNA. Terms of the agreement were not disclosed.
Source: China Biotoday
